全文获取类型
收费全文 | 10573篇 |
免费 | 655篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 412篇 |
妇产科学 | 370篇 |
基础医学 | 1349篇 |
口腔科学 | 83篇 |
临床医学 | 1292篇 |
内科学 | 1844篇 |
皮肤病学 | 204篇 |
神经病学 | 1006篇 |
特种医学 | 230篇 |
外科学 | 1269篇 |
综合类 | 75篇 |
一般理论 | 6篇 |
预防医学 | 1268篇 |
眼科学 | 169篇 |
药学 | 793篇 |
中国医学 | 4篇 |
肿瘤学 | 810篇 |
出版年
2024年 | 12篇 |
2023年 | 100篇 |
2022年 | 169篇 |
2021年 | 328篇 |
2020年 | 173篇 |
2019年 | 323篇 |
2018年 | 377篇 |
2017年 | 267篇 |
2016年 | 299篇 |
2015年 | 282篇 |
2014年 | 411篇 |
2013年 | 636篇 |
2012年 | 1003篇 |
2011年 | 944篇 |
2010年 | 486篇 |
2009年 | 429篇 |
2008年 | 770篇 |
2007年 | 775篇 |
2006年 | 657篇 |
2005年 | 641篇 |
2004年 | 625篇 |
2003年 | 509篇 |
2002年 | 449篇 |
2001年 | 63篇 |
2000年 | 51篇 |
1999年 | 57篇 |
1998年 | 71篇 |
1997年 | 62篇 |
1996年 | 43篇 |
1995年 | 24篇 |
1994年 | 40篇 |
1993年 | 27篇 |
1992年 | 19篇 |
1991年 | 18篇 |
1990年 | 16篇 |
1989年 | 12篇 |
1988年 | 10篇 |
1987年 | 9篇 |
1986年 | 9篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 12篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1972年 | 2篇 |
1910年 | 1篇 |
1909年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 12 毫秒
81.
82.
Howard H Bailey Dona B Alberti James P Thomas Daniel L Mulkerin Kimberly A Binger Marco M Gottardis Robert E Martell George Wilding 《Clinical cancer research》2007,13(12):3623-3629
PURPOSE: To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered paclitaxel and BMS-214662, a novel farnesyl transferase inhibitor. EXPERIMENTAL DESIGN: Patients were treated every week as tolerated with i.v. paclitaxel (fixed dose, 80 mg/m(2)/wk) administered over 1 h followed by i.v. BMS-214662 (escalating doses, 80-245 mg/m(2)/wk) over 1 h starting 30 min after completion of paclitaxel. RESULTS: Twenty-six patients received 94 courses (one course, 21 days) of study treatment. Two patients received five courses of BMS-214662 as a weekly 24-h infusion (209 mg/m(2)/wk). The most common toxicities were grade 1 to 2 nausea/vomiting and/or diarrhea. DLTs observed at or near the MTD (200 mg/m(2)/wk) were grade 4 febrile neutropenia with sepsis occurring on day 2 of course 1 (245 mg/m(2)/wk), reversible grade 3 to 4 serum transaminase increases on day 2, and grade 3 diarrhea (200 and 245 mg/m(2)/wk). Objective partial responses were observed in patients with pretreated head and neck, ovarian, and hormone-refractory prostate carcinomas, and leiomyosarcoma. The observed pharmacokinetics of paclitaxel and BMS-214662 imply no interaction between the two. Significant inhibition (>80%) of farnesyl transferase activity in peripheral mononuclear cells was observed at the end of BMS-214662 infusion. CONCLUSIONS: Pretreated patients with advanced malignancies can tolerate weekly paclitaxel and BMS-214662 at doses that achieve objective clinical benefit. Due to multiple DLTs occurring at the expanded MTD, the recommended phase 2 dose and schedule is paclitaxel (80 mg/m(2) over 1 h) and BMS-214662 (160 mg/m(2) over 1 h) administered weekly. 相似文献
83.
John G. Baust Kristi K. Snyder Kimberly L. Santucci Anthony T. Robilotto Robert G. Van Buskirk John M. Baust 《International journal of hyperthermia》2019,36(2):10-16
AbstractCryoablation (CA) is unique as the singular energy deprivation therapy that impacts all cellular processes. CA is independent of cell cycle stage and degree of cellular stemness. Importantly, CA is typically applied as a non-repetitive (single session) treatment that does not support adaptative mutagenesis as do many repetitive therapies. CA is characterized by the launch of multiple forms of cell death including (a) ice-related physical damage, (b) initiation of cellular stress responses (kill switch activation) and launch of necrosis and apoptosis, (c) vascular stasis, and (d) likely activation of ablative immune responses. CA is not without limitation related to the thermal gradient formed between cryoprobe surface (~?185°C) and the distal surface of the freeze zone (~0°C) requiring freeze margin extension beyond the tumor boundary (up to ~1?cm). This limitation is mitigated in part by commonly applied dual freeze thaw cycles and the use of freeze sensitizing adjuvants. This review will (1) identify the cascade of damaging effects of the freeze–thaw process, its physical and molecular-based relationships, (2) a likely immunological involvement (abscopic effect), and (3) explore the use of freeze-sensitizing adjuvants necessary to limit freezing beyond the tumor margin. 相似文献
84.
Rebecca L. Siegel MPH Kimberly D. Miller MPH Stacey A. Fedewa PhD Dennis J. Ahnen MD Reinier G. S. Meester PhD Afsaneh Barzi MD PhD Ahmedin Jemal DVM PhD 《CA: a cancer journal for clinicians》2017,67(3):177-193
Colorectal cancer (CRC) is one of the most common malignancies in the United States. Every 3 years, the American Cancer Society provides an update of CRC incidence, survival, and mortality rates and trends. Incidence data through 2013 were provided by the Surveillance, Epidemiology, and End Results program, the National Program of Cancer Registries, and the North American Association of Central Cancer Registries. Mortality data through 2014 were provided by the National Center for Health Statistics. CRC incidence rates are highest in Alaska Natives and blacks and lowest in Asian/Pacific Islanders, and they are 30% to 40% higher in men than in women. Recent temporal patterns are generally similar by race and sex, but differ by age. Between 2000 and 2013, incidence rates in adults aged ≥50 years declined by 32%, with the drop largest for distal tumors in people aged ≥65 years (incidence rate ratio [IRR], 0.50; 95% confidence interval [95% CI], 0.48‐0.52) and smallest for rectal tumors in ages 50 to 64 years (male IRR, 0.91; 95% CI, 0.85‐0.96; female IRR, 1.00; 95% CI, 0.93‐1.08). Overall CRC incidence in individuals ages ≥50 years declined from 2009 to 2013 in every state except Arkansas, with the decrease exceeding 5% annually in 7 states; however, rectal tumor incidence in those ages 50 to 64 years was stable in most states. Among adults aged <50 years, CRC incidence rates increased by 22% from 2000 to 2013, driven solely by tumors in the distal colon (IRR, 1.24; 95% CI, 1.13‐1.35) and rectum (IRR, 1.22; 95% CI, 1.13‐1.31). Similar to incidence patterns, CRC death rates decreased by 34% among individuals aged ≥50 years during 2000 through 2014, but increased by 13% in those aged <50 years. Progress against CRC can be accelerated by increasing initiation of screening at age 50 years (average risk) or earlier (eg, family history of CRC/advanced adenomas) and eliminating disparities in high‐quality treatment. In addition, research is needed to elucidate causes for increasing CRC in young adults. CA Cancer J Clin 2017. © 2017 American Cancer Society. CA Cancer J Clin 2017;67:177–193 . © 2017 American Cancer Society . 相似文献
85.
Kimberly A Bertrand Rulla M Tamimi Christopher G Scott Matthew R Jensen V Shane Pankratz Daniel Visscher Aaron Norman Fergus Couch John Shepherd Bo Fan Yunn-Yi Chen Lin Ma Andrew H Beck Steven R Cummings Karla Kerlikowske Celine M Vachon 《Breast cancer research : BCR》2013,15(6):R104
Introduction
Understanding whether mammographic density (MD) is associated with all breast tumor subtypes and whether the strength of association varies by age is important for utilizing MD in risk models.Methods
Data were pooled from six studies including 3414 women with breast cancer and 7199 without who underwent screening mammography. Percent MD was assessed from digitized film-screen mammograms using a computer-assisted threshold technique. We used polytomous logistic regression to calculate breast cancer odds according to tumor type, histopathological characteristics, and receptor (estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER2)) status by age (<55, 55–64, and ≥65 years).Results
MD was positively associated with risk of invasive tumors across all ages, with a two-fold increased risk for high (>51%) versus average density (11-25%). Women ages <55 years with high MD had stronger increased risk of ductal carcinoma in situ (DCIS) compared to women ages 55–64 and ≥65 years (Page-interaction = 0.02). Among all ages, MD had a stronger association with large (>2.1 cm) versus small tumors and positive versus negative lymph node status (P’s < 0.01). For women ages <55 years, there was a stronger association of MD with ER-negative breast cancer than ER-positive tumors compared to women ages 55–64 and ≥65 years (Page-interaction = 0.04). MD was positively associated with both HER2-negative and HER2-positive tumors within each age group.Conclusion
MD is strongly associated with all breast cancer subtypes, but particularly tumors of large size and positive lymph nodes across all ages, and ER-negative status among women ages <55 years, suggesting high MD may play an important role in tumor aggressiveness, especially in younger women. 相似文献86.
Catherine E. Arnold Logan J. Voegtly Emily K. Stefanov Matthew R. Lueder Andrea E. Luquette Robin H. Miller Haven L. Miner Andrew J. Bennett Lindsay Glang Tara N. McGinnis Kristie E. Reisinger Jae W. Dugan Michael A. Mangat Daniel J. Silberger Rebecca L. Pavlicek Chaselynn M. Watters Gregory K. Rice Francisco Malagon Regina Z. Cer Stephen M. Eggan Kimberly A. Bishop-Lilly 《Viruses》2022,14(9)
The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the disparity between developed and developing countries for infectious disease surveillance and the sequencing of pathogen genomes. The majority of SARS-CoV-2 sequences published are from Europe, North America, and Asia. Between April 2020 and January 2022, 795 SARS-CoV-2-positive nares swabs from individuals in the U.S. Navy installation Camp Lemonnier, Djibouti, were collected, sequenced, and analyzed. In this study, we described the results of genomic sequencing and analysis for 589 samples, the first published viral sequences for Djibouti, including 196 cases of vaccine breakthrough infections. This study contributes to the knowledge base of circulating SARS-CoV-2 lineages in the under-sampled country of Djibouti, where only 716 total genome sequences are available at time of publication. Our analysis resulted in the detection of circulating variants of concern, mutations of interest in lineages in which those mutations are not common, and emerging spike mutations. 相似文献
87.
Kimberly Loo Hannah L Kalvin Katherine S Panageas Vivian Park Michael A Postow 《The oncologist》2022,27(9):e755
BackgroundLittle is known about patient outcomes with advanced melanoma following inpatient initiation or continuation of immune checkpoint blockade (ICB).Methods and ResultsWe conducted a single institution retrospective case series of advanced melanoma patients who initiated ICB as an inpatient (initial inpatient cohort, n = 9), or continued ICB as an inpatient after previously starting as an outpatient (outpatient then inpatient cohort, n = 5). One patient had a partial response to ICB initiated as an inpatient, but ultimately died of melanoma after 13.5 months. Median overall survival for initial inpatient cohort was 1.0 month (95% CI: 0.2-11.2), and 1.4 months (95% CI: 0.4-58.0) for the outpatient then inpatient cohort. Three patients were alive >6 months after inpatient ICB administration.ConclusionDespite overall poor outcomes, some patients may benefit from inpatient ICB. This study provides additional information for clinicians to appropriately counsel patients on expectations following inpatient ICB. 相似文献
88.
89.
Hailin Chen Tengteng Yu Liang Lin Lijie Xing Shih-Feng Cho Kenneth Wen Kimberly Aardalen Adwait Oka Joni Lam Mike Daley Haihui Lu Nikhil Munshi Kenneth C. Anderson Yu-Tzu Tai 《Blood cancer journal》2022,12(8)
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs). GSIs-induced membrane BCMA (mBCMA) accumulation reached near maximum within 4 h and sustained over 42h-study period on MM cell lines and patient MM cells. GSIs, i.e., 2 nM LY-411575 or 1 μM DAPT, robustly increased mBCMA densities on CD138+ but not CD3+ patient cells, concomitantly with minimum soluble/shed BCMA (sBCMA) in 1 day-culture supernatants. In ex vivo MM-T-cell co-cultures, GSIs overcame sBCMA-inhibited MM cell lysis and further enhanced autologous patient MM cell lysis induced by BCMAxCD3 BisAbs, accompanied by significantly enhanced cytolytic markers (CD107a, IFNγ, IL2, and TNFα) in patient T cells. In longer 7 day-co-cultures, LY-411575 minimally affected BCMAxCD3 BisAb (PL33)-induced transient expression of checkpoint (PD1, TIGIT, TIM3, LAG3) and co-stimulatory (41BB, CD28) proteins, as well as time-dependent increases in % effector memory/central memory subsets and CD8/CD4 ratios in patient T cells. Importantly, LY41157 rapidly cleared sBCMA from circulation of MM-bearing NSG mice reconstituted with human T cells and significantly enhanced anti-MM efficacy of PL33 with prolonged host survival. Taken together, these results further support ongoing combination BCMA-targeting immunotherapies with GSI clinical studies to improve patient outcome.Subject terms: Cancer immunotherapy, Immunotherapy 相似文献
90.
Kimberly M. Baker 《Substance use & misuse》2016,51(4):489-497
Background: Previous research on addiction themed reality television shows has focused on the depiction of addiction and treatment and has concluded that these shows reinforce stigma. Existing research has not investigated the depiction of treatment professionals in these series. Objectives: This study fills the gap in existing research by analyzing the representations of treatment professionals in reality television shows, including the ways that the shows are edited, the statements made by treatment professionals, and interactions between treatment professionals and laypersons. Methods: The data for this study was drawn from two popular reality shows Intervention and Celebrity Rehab with Dr. Drew. Using a total of 117 episodes, a qualitative content analysis of the representations of treatment professionals in the two series was conducted. Results: The data reveal the ways that depictions of treatment professionals are carefully controlled compared to those of people with substance use issues. In addition, treatment professionals are granted opportunities to interpret, explain, and diagnose the behaviors and experiences of people with substance use problem. Finally, when confronted with resistance treatment professionals assert their authority and demand compliance with their orders. Conclusions/Importance: In strategically presenting treatment professionals in sharp contrast to people with substance use problems, these portrayals of treatment professionals actually reinforce rather than contradict the stigma of addiction. 相似文献